Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
NRG Oncology
Stanford University
Novartis
Pfizer
ADC Therapeutics S.A.
Eli Lilly and Company
Hoffmann-La Roche
Genmab
Nektar Therapeutics
Nektar Therapeutics
Ludwig Institute for Cancer Research
Incyte Corporation
Duke University
Calithera Biosciences, Inc
Incyte Corporation
Gilead Sciences
Incyte Corporation
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Stanford University
Pfizer
Stanford University
GlaxoSmithKline
Merck Sharp & Dohme LLC
GE Healthcare
INSYS Therapeutics Inc
Altor BioScience